BioNTech SE Sponsored ADR

BNTX Healthcare Biotechnology

BioNTech SE Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 9.07% from fiscal 2024. In the quarter to June 2026, revenue fell 58.5%, EPS fell 107.1%, free cash flow fell 342.0% and total debt rose 20.1%, each against the same quarter a year earlier.

87.57 2.63 −2.92%
Market cap
$22.7B
P/E
0.0×
Fwd P/E
−17.4×
Dividend yield
—
F-score
4/9
Altman Z
n/a
Beneish M
−2.74
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

4 5 3 2
ROE
(2.99%) (6.01%) (7.03%) (9.53%)
ROA
(2.57%) (5.22%) (6.26%) (8.24%)
ROIC
(13.11%) (19.03%) (22.28%) (38.39%)
Return on Tangible Assets
(3.72%) (7.53%) (8.44%) (11.87%)
Average Days of Receivables
93.74 124.23 80.73 33.00
Free Cash Flow per Share
(5.15) (1.35) 2.22 1.98
Free Cash Flow
(1,231.70) (326.41) 563.49 500.72
Other line items

Show all line items

Columns are period end dates